|本期目录/Table of Contents|

[1]张 凯,胡文星,赵守城,等.依折麦布联合舒洛地特对高龄冠心病和糖尿病患者调脂、抗炎作用的临床观察[J].医学研究与战创伤救治(原医学研究生学报),2012,14(05):428-431.
　ZHANG Kai,HU Wen-xing,ZHAO Shou-cheng,et al.Clinical observation of ezetimibe co-administration with sulodexide adjusting lipids and anti-inflammation in elderly patients with CHD and DM[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(05):428-431.
点击复制

依折麦布联合舒洛地特对高龄冠心病和糖尿病患者调脂、抗炎作用的临床观察()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第14卷
期数:
2012年05期
页码:
428-431
栏目:
出版日期:
2012-09-20

文章信息/Info

Title:
Clinical observation of ezetimibe co-administration with sulodexide adjusting lipids and anti-inflammation in elderly patients with CHD and DM
文章编号:
1672-271X(2012)05-0428-04
作者:
张 凯1; 胡文星2; 赵守城1; 王 忠1; 苑小历3
1.211131 江苏南京,南京军区南京总医院疗养区内科;2.210002 江苏南京,南京军区南京总医院皮肤科;3.210002 江苏南京,南京军区南京总医院干部保健科
Author(s):
ZHANG Kai1; HU Wen-xing2; ZHAO Shou-cheng1; WANG Zhong1; YUAN Xiao-li3
1.Department of Internal Medicine，Sanatorium Branch of Nanjing General Hospital of Nanjing Military Command，PLA，Nanjing，Jiangsu 211131,China；2.Department of Dermatology，3.Department of Cadre Health Caring，Nanjing General Hospital of Nanjing Military Command，PLA，Nanjing，Jiangsu 210002，China
关键词:
依折麦布; 舒洛地特; 辛伐他汀; 调脂; 肿瘤坏死因子-α; C反应蛋白
Keywords:
ezetimibe; sulodexide; simvastatin; lipid-adjusting; TNF-α; CRP
分类号:
R540.4
DOI:
-
文献标志码:
A
摘要:
目的 探讨依折麦布联合舒洛地特对高龄冠心病和糖尿病患者全面调脂、抗炎降低肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)的作用及安全性。方法 选取高龄冠心病、糖尿病患者180例，随机均分为三组。试验组:依折麦布/舒洛地特组(依/舒组)，给予依折麦布片 10 mg 口服，1次/d，舒洛地特胶囊 250LSU 口服，2次/d；对照组一:依折麦布/辛伐他汀组(依/辛组)，给予依折麦布片10 mg 口服，1次/d，辛伐他汀片 20 mg 口服，1次/d；对照组二:辛伐他汀组(辛组)，给予辛伐他汀片 20 mg 口服，1次/d。所有患者在治疗前及治疗后4周、12周末空腹采血，检测总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)。在治疗前及治疗12周末空腹采血测定血浆TNF-α、CRP。结果 ①治疗后三组TC、LDL-C均明显下降(P<0.05)。12周末，依/辛组较依/舒组、依/舒组较辛组TC、LDL-C变化显著(P<0.05)。②12周末，依/舒组HDL-C明显升高(P<0.05)。③4周、12周末，依/舒组、依/辛组TG明显下降(P<0.05)，依/舒组较依/辛组，TG下降显著(P<0.05)。④12周末，依/舒组TC、LDL-C、HDL-C、TG的达标率皆优于辛组(P<0.05)，TG的达标率优于依/辛组。依/辛组TC、LDL-C达标率在三组中最高，皆为100% 。⑤三组在12周末血浆TNF-α、CRP较基线水平明显降低(P<0.05)，彼此之间无显著差异。结论 依折麦布、舒洛地特联用于冠心病、2型糖尿病高龄患者，有良好的全面调脂、抗炎作用，安全性佳，还能发挥舒洛地特的经典临床药理作用，是一种有前途的临床用药方案。
Abstract:
Objective To investigate the therapeutic effectiveness and safety of ezetimibe combined with sulodexide on overall lipid-adjusting,lowering TNF-αand CRP in elderly patients with CHD and DM.Methods 180 elderly patients with CHD,DM were divided equally into 3 groups.All the subjects received therapy as follows:①10 mg ezetimibe qd.+250 LSU sulodexide bid (the observed group，n=60)；②10 mg ezetimibe qd +20 mg simvastatin qd.(the 1st control group,n=60)；③20 mg simvastatin qd.(the 2nd control group,n=60).Serum total cholesterol (TC),low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol (HDL-C),total triglyeride (TG) were determined before treatment,at 4 weeks and at 12 weeks; serum tumor necrosis factor-α (TNF-α) and C- reactive protein (CRP) were also determined before treatment and at 12 weeks.Results ①TC and LDL-C in the 3 groups were significantly lower (P<0.05) after treatment compared with the basic level.TC and LDL-C were significantly lower in the 1st control group than the observed group (P<0.05)，and lower in the observed group than the 2nd control group (P<0.05)at 12 weeks.②HDL-C was significantly higher in the observed group compared with the basic level at 12 weeks.③TG was significantly lower in the observed group and the 1st control group compared with their respective baseline (P<0.05)，and in the observed group than the 1st control group at 4 weeks and at 12 weeks (P<0.05).④At 12 weeks，the compliance rates of TC，LDL-C，HDL-C and TG in the observed group were higher than in the 2nd control group respectively；the compliance rate of TG in the observed group was higher than in the 1st control group；the compliance rates of TC and LDL-C in the 1st control group were the highest (reached at 100%) than the other 2 groups.⑤TNF-α and CRP were significantly lower in the 3 groups compared with their respective baseline (P<0.05),and there was no difference on the therapeutic effectiveness between in the 3 groups.Conclusion Ezetimibe co-administration with sulodexide in elderly patients with CHD and DM can not only show pleiotropic effects on overall lipid-adjusting，anti-inflammation,good safeness,but also can educes classical pharmacological actions of sulodexide,so it is a prospective clinical medication combination.

参考文献/References:

[1]Bays HE，Neff D，Tomassini JE，et al．Ezetimibe:cholesterol lowering and beyond[J]．Expert Rev Cardiovasc Ther，2008，6(4):447-470．
[2]Fleg JL,Mete M,Howard BV，et al．Effect of statins alone versus statins plus etetimibe on carotid atherosclerosis in type 2 diabetes the SANDS(Stop Atherosclerosis in Native Diabetics Study) trial[J]．J Am Coll Cardiol，2008，52(25):2198-2205．
[3]Guyton JR，Brown BG,Fazio S，et al．Lipid-altering efficacy and safety of ezetimibe／simvastatin coadministered with extended-release niacin in patiens with type Ⅱa or type Ⅱb hyperlipidemia[J]．J Am Coll Cardiol，2008，51(16):1564-1572．
[4]Davdson MH,Mcgarry T，Bettis R，et al．Ezetimibe coadministered with simvastatin[J]．J Am Coll Cardiol，2002，40(12):2125-2134．
[5]Radakrishnamurthy B,Sharma C，Bhandaru RR，et al．Studies of chemical and biologic properties of a fraction of sulodexide，a heparinlike glycolsaminoglycan[J]．Atherosclerosis，1986，60(2):141-149．
[6]Radakrishnamurthy B，Ruiz HA，Srinivasan SR，et al．Studies on glycosaminoglycan composition and biologic activity of VESSEL，a hypolipidemic agent[J]．Atherosclerosis，1978，31(2):217-229．
[7]Paraskevas KI，Baker DM，Vrentzos GE，et al．The role of fibrinogen and fibrinolysis in peripheral arterial disease[J]．Thromb Res，2008，122(1):1-12．
[8]林 杰，陈力平，肖 立．同型半胱氨酸、C反应蛋白与血脂相关指标对冠心病诊断的比较[J].东南国防医药，2011，13(6):509-511．
[9]中国成人血脂异常防治指南制定联合委员会．中国成人血脂异常防治指南[J]．中华心血管病杂志，2007，35(5):399-401．
[10]高海青．第二次中国临床血脂控制状况多中心协作暨REALITY研究[J]．华夏医药，2007，2(2):117-124．
[11]任绍学，陈亨芸，罗助荣．阿托伐他汀治疗老年冠心病合并血脂异常48例[J].东南国防医药，2008，10(4):293-294．
[12]van Himbergen TM，Matthan NR，Resteghini NA，et al．Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers[J]．J Lipid Res，2009，50(4):730-739．
[13]Kajinami K，Takekoshi N.Cholesterol absorption inhibitors in development as potential therapeutics[J]．Exp Opin Investig Drugs，2002，11(6):831-835．
[14]Kastelein JJP，Akdim F，Stroes ESC，et al．Simvastatin with or without ezetimibe in familial hypercholesterolemia[J]．N Engl J Med，2008,359(5):529-531.
[15]薛发刚，姬胜利，张云峰．多组分糖胺聚糖药物舒洛地特研究进展[J].中国生化药物杂志，2009，30(6):430-432．

相似文献/References:

[1]龚春水,许树根,胡玉清,等.舒洛地特联合坎地沙坦治疗糖尿病肾病4期患者临床疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2017,19(03):248.[doi:10.3969/j.issn.1672-271X.2017.03.006]
　GONG Chun-shui,XU Shu-gen,HU Yu-qing,et al.Efficacy observation of sulodexide and candesartan on 48 cases with diabetic nephropathyIV stage[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(05):248.[doi:10.3969/j.issn.1672-271X.2017.03.006]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2012-09-20